TransMedics Group (TMDX) Tops Q4 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to TransMedics Group (TMDX) Tops Q4 EPS by 2c, Revenues Beat
March 2, 2021 9:28 AM EST
Today's Pre-Open Stock Movers
Inuvo (NYSE: INUV) 24% HIGHER; On February 24, 2021, Vertro, Inc., a wholly-owned subsidiary of Inuvo, Inc. entered into a Google Services Agreement with Google LLC, effective as of March 1, 2021.
FibroGen, Inc. (Nasdaq: FGEN) 17.5% LOWER; FibroGen... More
March 2, 2021 6:14 AM EST
Oppenheimer analyst Suraj Kalia raised the price target on TransMedics Group (NASDAQ: TMDX) to $40.00 (from $25.00) while maintaining an Outperform rating.
The analyst commented, "After close (3/1), TransMedics announced FDA has communicated its intent to hold a Circulatory Systems Device Advisory Panel meeting on 4/6. While... More
March 1, 2021 4:17 PM EST
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA's Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory... More
